Quick Take
Genetic information company Invitae (NVTA) has announced agreements to acquire two companies, privately-held Good Start Genetics and CombiMatrix (CBMX).
The target companies offer a range of prenatal and post-pregnancy genetic-based screening services for clinicians and their patients.
Invitae is acquiring these two firms as part of an ongoing strategy to create a genetic information cafeteria that provides a wide range of diagnostics options.
Target Companies
Cambridge, Massachusetts-based Good Start was founded in 2008 to develop prenatal screening tests for persons wishing to have children.
Management is headed by CEO Jeffrey Luber, who has been with the company since 2014 and was previously CEO of EXACT Sciences (EXAS) during its turnaround and recapitalization. He was also co-founder and Vice President Corporate Development at SynapDx.
Below is a brief overview video about GoodStarts carrier screening:
(Source: Motivity Video)
Good Start has developed three types of tests:
Good Start had raised $32 million in investment from top tier investors such as OrbiMed, Safeguard Scientifics (SFE) and SV Health Investors.
CombiMatrix, which held its IPO in 2002, provides miscarriage analysis and advanced DNA testing for in-vitro fertility screening and determining genetic abnormalities involved in miscarriage & pediatric developmental disorders.
Prior to the acquisition announcement, CombiMatrix had a market capitalization of approximately $14.4 million.
Acquisition Terms and Rationale
For Good Start, Invitae intends to pay cash of $18.3 million, 1.65 million shares of Invitae stock ($15 million worth) and the assumption of Good Starts obligations, for a total transaction value of approximately $39.3 million.
For CombiMatrix, Invitae intends to pay up to $27 million in NVTA stock for CombiMatrix stock, RSUs and in-the-money options, plus up to $6 million in NVTA stock for Series F warrants, which were originally sold in 2016 as part of an $8 million financing. If holders of less than 90% of outstanding Series F warrants tender, then Invitae has the option to terminate the acquisition.
Notably, the deal announcement states that the cost to Invitae of those warrants may increase as follows,
To the extent the Series F warrants are not exchanged and are either exercised or assumed as part of the acquisition, the consideration payable by Invitae could increase by up to approximately $15.0 million in shares of Invitae, or approximately 1.58 million shares, subject to adjustment based upon a net cash calculation for CombiMatrix at the time of the acquisition.
Thus, Invitae is on the hook for up to an additional $15 million in stock consideration for CombiMatrix pertaining to what the Series F warrant holders choose to do.
So, to sum up both transactions, Invitae is spending $18.3 million in cash, issuing $48 million worth of stock and is potentially on the hook for an additional $15 million in stock, for a total combined deal value of $81.3 million.
Invitaes most recent 10-Q for the quarter ended March 31, 2017, indicated cash and marketable securities of $96.7 million and total liabilities of $70.3 million, so it appears the company has ample resources to pay for these two acquisitions since they are mostly paid for with stock.
The rationale for Invitaes moves to acquire both companies is to expand its offerings to families both before pregnancy and after childbirth or miscarriage.
This in turn is part of Invitaes strategic approach of providing genetic information to individuals throughout their life span.
As Invitae CEO Sean George stated in the deal announcement,
This is a transformative moment for Invitae, for our industry, and importantly for patients. By acquiring Good Start and CombiMatrix, Invitae intends to create the industry's first comprehensive genetic information platform providing high-quality, affordable genetic information coupled with world-class clinical expertise to inform healthcare decisions throughout every stage of an individual's life. We believe the strength of our existing platform, strategic acquisitions like these and our network of partners will fuel continued growth and further establish Invitae as a leading genetic information service provider.
Invitae management hasnt been shy about acquiring companies as it sees fit. I previously wrote on the companies last acquisition in June in my article, Invitae Acquires CancerGene Connect for Patient Family History Collection.
Invitae appears to be assembling a veritable cafeteria of options for genetic information for consumers, healthcare providers and other market participants.
Investors like what they see so far, although Invitaes stock in the past year has largely moved within a range of $6.00 per share to $11.00 per share. The stock is up 7.75% on the current two acquisition deal announcement:
(Source: Seeking Alpha)
It is likely that both acquisitions will be a drag on EPS in the near term, but promise to increase Invitaes breadth of service offerings as management appears to intend it to become a one-stop shop for genetic information.
The big question is whether or not that is a viable model in the nascent market for genetic information. Acquiring companies on the cheap certainly helps, although Im not convinced that these acquisitions are necessarily cheap.
So, the jury is out, and management will need to prove the value of these transactions over the next 12 to 18 months.
I write about M&A deals, public company investments in technology startups, insider activity, and IPOs. Click the Follow button next to my name at the top or bottom of this article if you want to receive future articles automatically.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
Continued here:
Invitae To Acquire Good Start Genetics And CombiMatrix - Seeking Alpha
- Commentary: This genetics firm didn't resurrect the extinct dire wolf, but did achieve a breakthrough in hype - Los Angeles Times - April 27th, 2025 [April 27th, 2025]
- WHAT THE TECH? How the sale of genetics testing company could impact you - Local 3 News - April 27th, 2025 [April 27th, 2025]
- Genetics of circulating proteins in newborn babies at high risk of type 1 diabetes - Nature - April 27th, 2025 [April 27th, 2025]
- Daily briefing: Potato pangenome reveals the complex genetics of the humble spud - Nature - April 27th, 2025 [April 27th, 2025]
- Chinese and other global scientists jointly solve genetics mystery of Mendel's peas - China Daily - April 27th, 2025 [April 27th, 2025]
- Leveraging genetics to understand ADAR1-mediated RNA editing in health and disease - Nature - April 19th, 2025 [April 19th, 2025]
- Zevra Announces Publication of MIPLYFFA Mechanism of Action Manuscript in Molecular Genetics and Metabolism - Yahoo Finance - April 19th, 2025 [April 19th, 2025]
- Myriad Genetics price target lowered to $9 from $11 at BofA - Yahoo Finance - April 19th, 2025 [April 19th, 2025]
- Genetics of hemophilia: Why mutations matter more than ever in diagnosis and treatment - Firstpost - April 19th, 2025 [April 19th, 2025]
- RFK Jr. sparks backlash with autism comments, dismissing genetics and calling disorder preventable - 13newsnow.com - April 19th, 2025 [April 19th, 2025]
- The Crucial Role Of Genetics In Rare Diseases - BW Healthcare World - April 19th, 2025 [April 19th, 2025]
- How AI and genetics are revolutionizing psychiatric diagnosis and treatment [PODCAST] - KevinMD.com - April 10th, 2025 [April 10th, 2025]
- Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases -... - April 10th, 2025 [April 10th, 2025]
- A genetics company just revived the dire wolf, sort of - Boy Genius Report - April 10th, 2025 [April 10th, 2025]
- Slammed 25% Opus Genetics, Inc. (NASDAQ:IRD) Screens Well Here But There Might Be A Catch - simplywall.st - April 10th, 2025 [April 10th, 2025]
- Do genetics hold the key to the US' European green crab problem? - Oceanographic Magazine - April 10th, 2025 [April 10th, 2025]
- Sequence errors are canaries in a coal mine in genetics studies, sleuth says - Retraction Watch - March 30th, 2025 [March 30th, 2025]
- Significance of noninvasive prenatal testing using massively parallel sequencing in women with twin or vanishing twin pregnancies | Journal of Human... - March 30th, 2025 [March 30th, 2025]
- All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance - March 30th, 2025 [March 30th, 2025]
- 23andMe Stock Is Surging After a Bankruptcy Judge Cleared Genetics Business Sale. Heres Why You Need to Stay Far Away From ME Shares. - Barchart - March 30th, 2025 [March 30th, 2025]
- Dairy producers leverage genetics to optimize milk composition for processing - Feedstuffs - March 30th, 2025 [March 30th, 2025]
- Several Insiders Invested In Opus Genetics Flagging Positive News - Yahoo Finance - March 30th, 2025 [March 30th, 2025]
- Human genetics and biotechnology company 23andMe to pursue bankruptcy sale after failed prepetition attempt Case Profile - ION Analytics - March 30th, 2025 [March 30th, 2025]
- AP Biology Students At NLHS Explore Genetics With Build-A-Baby Monster Lab - EastTexasRadio.com - March 30th, 2025 [March 30th, 2025]
- Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance - March 15th, 2025 [March 15th, 2025]
- Helix Unveils Groundbreaking Real-World Insights at the ACMG Annual Clinical Genetics Meeting, Driving Clinical Care Forward - PR Newswire - March 15th, 2025 [March 15th, 2025]
- S2 Episode 3: Molecular Classification and Genetics of Endometrial Cancer - Medscape - March 15th, 2025 [March 15th, 2025]
- Fowl Play: How Chicken Genetics Barons Created the Egg Crisis - The Big Newsletter - March 15th, 2025 [March 15th, 2025]
- Exposure to violence alters human genetics for future generations - Earth.com - March 5th, 2025 [March 5th, 2025]
- Family-based genetics identifies association of CUBN IL1RL1 and PRKN variants with leprosy in Bangladesh - Nature.com - March 5th, 2025 [March 5th, 2025]
- The role of genetics in infant hearing loss: What parents need to know - The Times of India - March 5th, 2025 [March 5th, 2025]
- Analyzing Genetics May Lead to Better Contraceptive Experiences for Women - Yale School of Medicine - March 5th, 2025 [March 5th, 2025]
- Fulgent Genetics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance - March 5th, 2025 [March 5th, 2025]
- Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the... - February 25th, 2025 [February 25th, 2025]
- Dual recombinase-mediated intersectional genetics defines the functional heterogeneity of neural stem cells in adult hippocampus - Nature.com - February 25th, 2025 [February 25th, 2025]
- Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - Yahoo Finance - February 25th, 2025 [February 25th, 2025]
- The Genetics of Creativity: Can Creative Talent Be Inherited? - Etownian - February 25th, 2025 [February 25th, 2025]
- Weight and metabolism determined more by genetics than diet - WVTF - February 25th, 2025 [February 25th, 2025]
- Beyond genetics: The biggest factors that influence health and aging - Earth.com - February 25th, 2025 [February 25th, 2025]
- Study finds lifestyle, environment have greater impact on lifespan than genetics - CBS Boston - February 25th, 2025 [February 25th, 2025]
- 6 Things to Know About Genetics in GI Cancers - Gastroenterology & Endoscopy News - February 25th, 2025 [February 25th, 2025]
- Virologist Wendy Barclay: Wild avian viruses are mixing up their genetics all the time. Its like viral sex on steroids - The Guardian - February 3rd, 2025 [February 3rd, 2025]
- Do you find coffee too bitter? Scientists explain how your genetics and roasting process affect the flavour - Hindustan Times - February 3rd, 2025 [February 3rd, 2025]
- 2025 Illinois Performance Tested Bull Sale prioritizes trusted genetics for herd growth - Morning Ag Clips - - February 3rd, 2025 [February 3rd, 2025]
- Game-Changing Cancer Detection Tool Spots What Others Miss: New Breakthrough from SOPHiA GENETICS - StockTitan - February 3rd, 2025 [February 3rd, 2025]
- Integrative genetics and multiomics analysis reveal mechanisms and therapeutic targets in vitiligo highlighting JAK STAT pathway regulation of CTSS -... - January 23rd, 2025 [January 23rd, 2025]
- deCODE genetics: Complete recombination map of the human-genome, a major step in genetics - Financial Times - January 23rd, 2025 [January 23rd, 2025]
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - Yahoo Finance - January 23rd, 2025 [January 23rd, 2025]
- Bjarni V. Halldorsson and Kari Stefansson, scientists at deCODE genetics, discuss the paper: Complete recombination map of the human-genome, published... - January 23rd, 2025 [January 23rd, 2025]
- Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan - January 23rd, 2025 [January 23rd, 2025]
- Genetics, brain development, and mental health shape teen eating - News-Medical.Net - January 15th, 2025 [January 15th, 2025]
- Building Better Flu Shots Based on Antibody Responses and Genetics - Vax-Before-Travel - January 15th, 2025 [January 15th, 2025]
- Its in the Genes: Weight and Metabolism Determined by Genetics More Than Diet - Cville Right Now - January 15th, 2025 [January 15th, 2025]
- It's in the genes: Weight and metabolism determined by genetics more than diet - Medical Xpress - January 15th, 2025 [January 15th, 2025]
- Trump and Musk are obsessed with genetics but theres no science behind their simplistic views - The Guardian - January 1st, 2025 [January 1st, 2025]
- From Stonehenge's origins to ice age baby genetics how well did you follow this year's top archaeology stories? - Livescience.com - January 1st, 2025 [January 1st, 2025]
- William Thilly, MIT genetics professor who invented Apple Jacks cereal, dies at 79 - The Boston Globe - January 1st, 2025 [January 1st, 2025]
- Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- With 54% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- Using the PERC Database to Gather Insights on Epilepsy Genetics: Julie Ziobro, MD, PhD; John Schreiber, MD - Neurology Live - December 23rd, 2024 [December 23rd, 2024]
- Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan - December 23rd, 2024 [December 23rd, 2024]
- Redecan Cannabis Launches New Limited-Edition Genetics and Expands Signature 'Wrapped & Redee' Pre-roll Line for the Holidays - Yahoo Finance - December 23rd, 2024 [December 23rd, 2024]
- Surprising yields, impressive genetics and an early harvest in 2024 Ohio Ag Net - Ohio's Country Journal and Ohio Ag Net - December 9th, 2024 [December 9th, 2024]
- Using music to help people with dementia; supporting breastfeeding radiologists; genetics and Type 2 diabetes; plus other news stories with VUMC... - December 9th, 2024 [December 9th, 2024]
- Genetics and suicideWhats the link? - Genetic Literacy Project - December 9th, 2024 [December 9th, 2024]
- Genetics is all fun and games for a Rochester card game creator - Rochester Post Bulletin - November 28th, 2024 [November 28th, 2024]
- Community engagement conduct for genetics and genomics research: a qualitative study of the experiences and perspectives of key stakeholders in Uganda... - November 28th, 2024 [November 28th, 2024]
- Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics - Nature.com - November 28th, 2024 [November 28th, 2024]
- Texas A&M Researchers Uncover Secrets Of Horse Genetics For Conservation, Breeding - Texas A&M University Today - November 20th, 2024 [November 20th, 2024]
- Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire - November 20th, 2024 [November 20th, 2024]
- Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance - November 20th, 2024 [November 20th, 2024]
- Precision mutational scanning: your multipass to the future of genetics - Nature.com - November 20th, 2024 [November 20th, 2024]
- Advancements of Haploid Technology in Crops: New Horizons in Breeding and Genetics - Frontiers - November 20th, 2024 [November 20th, 2024]
- Toward advances in retinoblastoma genetics in Kenya - Nature.com - November 12th, 2024 [November 12th, 2024]
- CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production - Nature.com - November 12th, 2024 [November 12th, 2024]
- Genetics Play Key Role in Animal Health and Welfare, Aggression and Handling - Farms.com - November 12th, 2024 [November 12th, 2024]
- Episode 174: Rudy Tanzi talks about genetics, aging and the hallmarks of Alzheimers - IHMC - October 26th, 2024 [October 26th, 2024]
- Ocuphire and Opus Genetics merge to develop IRD gene therapy - Pharmaceutical Technology - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - PR Newswire - October 26th, 2024 [October 26th, 2024]
- The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - WV News - October 26th, 2024 [October 26th, 2024]